Will out-of-pocket cash with Green Delta Insurance, MetLife Bangladesh, and Pragati Insurance health plans cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Avmapki Fakzynja Co-Pack is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by DGDA?

The DGDA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; DGDA review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Bangladeshi-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Bangladesh Medical and Dental Council (BMDC) and the DGDA verifies the active license; the DGDA application records both the prescribing physician and the dispensing facility.

Can I receive Avmapki Fakzynja Co-Pack at home?

The dispensing facility must be Bangladeshi-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Avmapki Fakzynja Co-Pack access in Bangladesh: the DGDA named-patient pathway

How patients in the People's Republic of Bangladesh legally obtain Avmapki Fakzynja Co-Pack (avutometinib and defactinib co-pack) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Bangladesh access Avmapki Fakzynja Co-Pack (avutometinib and defactinib co-pack) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy through the DGDA named-patient pathway, a Directorate General of Drug Administration-administered mechanism that allows a Bangladeshi-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in BDT.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Avmapki Fakzynja Co-Pack reaches patients in Bangladesh

Avmapki Fakzynja Co-Pack (avutometinib, a RAF/MEK clamp inhibiting MEK1/2 phosphorylation, plus defactinib, a focal adhesion kinase inhibitor, from Verastem Oncology, FDA-approved 8 May 2025 under accelerated approval for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy, label resource at accessdata.fda.gov) is not listed on the Directorate General of Drug Administration registered imported drugs database at dgdagov.info/registered-imported-drugs as of 2026-06-01. Bangladesh patients access the medicine under the case-by-case Permission to Import Unregistered or Foreign Medicine for Personal or Institutional Use, administered by DGDA under Section 13 of the Drugs (Control) Ordinance 1982 read with Section 14A which prohibits prescription of unregistered medicines absent DGDA permission, ordinance text at bdlaws.minlaw.gov.bd/act-623. The DGDA Guidelines on Import Procedures for Medical Products are at dgdagov.info guidance, with the Bangladesh Trade Portal Registration for Foreign Medicine procedure at bangladeshtradeportal.gov.bd. The application is filed to the Director General, DGDA, by the treating gynaecologic oncologist or institutional importer with a Bangladesh Medical and Dental Council-registered prescription, the KRAS mutation report from a recognised molecular pathology laboratory, prior systemic therapy history, the patient's national identification, and a pro-forma invoice. No public DGDA service-level agreement for processing time is documented; treatment is granted case by case. Each consignment requires a fresh DGDA permission letter presented to Bangladesh Customs.

Where Avmapki Fakzynja Co-Pack is dispensed in Bangladesh

The Avmapki Fakzynja Co-Pack is an oral two-drug regimen (twice-weekly avutometinib plus twice-daily defactinib on a 21-days-on, 7-days-off cycle per the FDA label) for adult women with KRAS-mutated recurrent low-grade serous ovarian cancer. Dispensing routes through gynaecologic oncology services at tertiary cancer hospitals with the diagnostic infrastructure for KRAS mutation testing and the surveillance capacity for ophthalmologic, cardiac, hepatic, and dermatologic monitoring per the FDA label. The National Institute of Cancer Research and Hospital Dhaka is Bangladesh's only specialised government tertiary cancer hospital, with Gynaecological Oncology service, at nicrh.gov.bd. Bangabandhu Sheikh Mujib Medical University Dhaka operates Medical Oncology, Gynaecological Oncology, and Paediatric Oncology services in a university-tertiary setting, at bsmmu.edu.bd. Dhaka Medical College Hospital provides general tertiary oncology. Ahsania Mission Cancer & General Hospital Dhaka operates as a charitable tertiary oncology centre. Among private tertiary nodes, Square Hospitals Dhaka, United Hospital Dhaka, Evercare Hospital Dhaka, and Labaid Specialized Hospital Dhaka publish gynaecologic oncology consultant rosters and are the most-frequent dispensing nodes for unregistered named-patient oncology imports. No public record of a Bangladesh-specific recurrent low-grade serous ovarian cancer registry comparable to international gynaecologic-oncology trial networks has been observed as of 2026-06-01.

What Avmapki Fakzynja Co-Pack costs in Bangladesh

Verastem Oncology has reported list pricing for the Avmapki Fakzynja Co-Pack in launch disclosures at approximately USD 39,000 per 28-day cycle, equating to roughly USD 470,000 per year of therapy at the labelled 21-days-on, 7-days-off schedule, sourced from manufacturer disclosures and Drugs@FDA at accessdata.fda.gov. No public local-currency benchmark for the Avmapki Fakzynja Co-Pack in BDT is observed on DGDA at dgda.gov.bd, in Bangladesh hospital pharmacy reporting, or in NICRH pricing reporting as of 2026-06-01, consistent with the drug not being DGDA-registered; do not estimate. Price snapshot: 2026-06-01. Cost layers stacked on the drug cost include international ambient freight (both component agents are stable oral solids at controlled room temperature per the FDA label), DGDA permission and customs handling, the dispensing oncology centre's drug-handling fee, the KRAS mutation testing fee where the laboratory is the dispensing centre rather than an upstream pathology lab, and the Reserve Meds concierge fee itemised separately on every firm quote. The non-commercial-import customs threshold of USD 7,000 per shipment from the US Department of Commerce country guide at trade.gov Bangladesh guide is exceeded by a typical Avmapki Fakzynja shipment; DGDA permission is the binding requirement.

Funding and access barriers for Avmapki Fakzynja Co-Pack in Bangladesh

Bangladesh has no nationwide universal health insurance scheme as of 2026-06-01. The Shasthyo Surokhsha Karmasuchi pilot operates in selected upazilas for below-poverty-line families; coverage of unregistered specialty oncology imports under SSK has not been documented. The National Institute of Cancer Research and Hospital and Bangabandhu Sheikh Mujib Medical University provide subsidised inpatient oncology care funded through Ministry of Health and Family Welfare budgets; specialty named-patient targeted-therapy oncology imports at originator pricing are not part of routine MOHFW procurement. The Honourable Prime Minister's Welfare Fund and the Honourable Prime Minister's Special Fund consider case-by-case grants for high-cost foreign-sourced cancer treatment; KRAS-targeted ovarian-cancer therapies are not subjects of any public bulletin from these funds as observed at the snapshot date. Bangladesh private insurers including Pragati Life Insurance, Delta Life Insurance, MetLife Bangladesh, Green Delta Insurance, Pioneer Insurance, and Sadharan Bima Corporation cover specialty oncology variably; private health insurance penetration is low. Bangladesh's out-of-pocket share of total health expenditure consistently sits above 65 percent per WHO and National Health Accounts reporting. The dominant funding pattern for an Avmapki Fakzynja Co-Pack case is family self-pay, supported where applicable by remittance from family members abroad and by charitable funding through institutions like Ahsania Mission Cancer & General Hospital. The Verastem Oncology US patient-assistance programme does not extend to international named-patient imports. KRAS mutation testing capacity in Bangladesh is concentrated at university and private molecular pathology laboratories; documentation of the testing laboratory and the assay used is part of the DGDA filing.

Recent regulatory and access news for Avmapki Fakzynja Co-Pack

The DGDA notices feed at dgda.gov.bd/all-categories-notices has not posted an avutometinib- or defactinib-specific notification over the last 12 months as of 2026-06-01. DGDA published the Guideline for Quality Assurance of Locally Sourced Medical Products on 2025-01-14 at dgda.portal.gov.bd policy, which addresses local manufacturing quality rather than personal-import oncology permissions. The Government of Bangladesh has continued consultation on a planned new medicine-regulation law to replace the 1982 Ordinance, reported by Dhaka Tribune at dhakatribune.com new law on medicine regulation; the law had not been gazetted at the snapshot date. No relevant local bulletins on Avmapki Fakzynja Co-Pack, KRAS-targeted ovarian cancer therapy, or low-grade serous ovarian cancer specifically in Bangladesh in the last 12 months have been observed as of 2026-06-01.

Where Reserve Meds fits in Avmapki Fakzynja Co-Pack cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace DGDA, and we do not replace your dispensing pharmacy. For Avmapki Fakzynja Co-Pack specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Bangladesh, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Avmapki Fakzynja Co-Pack case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the DGDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Bangladeshi tertiary specialty care concentrates at Square, Apollo Imperial, United, Evercare, and Labaid in Dhaka; the DGDA named-patient import authorisation is the standard mechanism for unregistered specialty medicines and is typically filed by the treating consultant at one of these centres.

Next step

If your Bangladeshi physician has prescribed Avmapki Fakzynja Co-Pack and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Avmapki Fakzynja Co Pack case Or message us on WhatsApp